4.3 Review

Immuno-Positron Emission Tomography in Cancer Models

Journal

SEMINARS IN NUCLEAR MEDICINE
Volume 40, Issue 3, Pages 182-189

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.semnuclmed.2009.12.004

Keywords

-

Funding

  1. Health Resources and Services Administration
  2. NIH [NIH-CA009035-34]
  3. NATIONAL CANCER INSTITUTE [T32CA009035] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Positron emission tomography (PET) is playing an increasingly important role in the diagnosis, staging, and monitoring response to treatment in a variety of cancers. Recent efforts have focused on immuno-PET, which uses antibody-based radiotracers, to image tumors based on expression of tumor-associated antigens. It is postulated that the specificity afforded by antibody targeting should both improve tumor detection and provide phenotypic information related to primary and metastatic lesions that will guide therapy decisions. Advances in antibody-engineering are providing the tools to develop antibody-based molecules with pharmacokinetic properties optimized for use as immuno-PET radiotracers. Coupled with technical advances in the design of PET scanners, immuno-PET holds promise to improve diagnostic imaging and to guide the use of targeted therapies. An overview of the preclinical immuno-PET studies in cancer models is reviewed here. Semin Nucl Med 40:182-189 (C) 2010 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available